{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:16:05Z","timestamp":1790666165878,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.tox.2011.08.009","type":"journal-article","created":{"date-parts":[[2011,8,16]],"date-time":"2011-08-16T13:13:24Z","timestamp":1313500404000},"page":"141-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Subchronic oral toxicity and metabolite profiling of the p53 stabilizing agent, CP-31398, in rats and dogs"],"prefix":"10.1016","volume":"289","author":[{"given":"William D.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Muzzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol J.","family":"Detrisac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izet M.","family":"Kapetanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levy","family":"Kopelovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tox.2011.08.009_bib0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.tips.2010.11.004","article-title":"Reactivation of p53: from peptides to small molecules","volume":"32","author":"Brown","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tox.2011.08.009_bib0010","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nrc2763","article-title":"Awakening guardian angels: drugging the p53 pathway","volume":"9","author":"Brown","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tox.2011.08.009_bib0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrclinonc.2010.174","article-title":"Translating p53 into the clinic","volume":"8","author":"Cheok","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tox.2011.08.009_bib0020","doi-asserted-by":"crossref","first-page":"45887","DOI":"10.1074\/jbc.M401854200","article-title":"CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73","volume":"279","author":"Demma","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tox.2011.08.009_bib0025","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1126\/science.286.5449.2507","article-title":"Pharmacological rescue of mutant p53 conformation and function","volume":"286","author":"Foster","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.tox.2011.08.009_bib0030","first-page":"4855","article-title":"Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis","volume":"54","author":"Greenblatt","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.tox.2011.08.009_bib0035","first-page":"121","article-title":"Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein","volume":"3","author":"Harris","year":"1996","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.tox.2011.08.009_bib0040","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1038\/sj.onc.1208615","article-title":"The p53 pathway: positive and negative feedback loops","volume":"24","author":"Harris","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.tox.2011.08.009_bib0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.1905840","article-title":"p53 mutations in human cancers","volume":"253","author":"Hollstein","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.tox.2011.08.009_bib0050","first-page":"500","article-title":"Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications","volume":"1","author":"Horowitz","year":"1999","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.tox.2011.08.009_bib0055","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1038\/sj.onc.1210291","article-title":"Structure\u2013function-rescue: the diverse nature of common p53 cancer mutants","volume":"26","author":"Joerger","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.tox.2011.08.009_bib0060","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1126\/science.2047879","article-title":"Identification of p53 as a sequence-specific DNA-binding protein","volume":"252","author":"Kern","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.tox.2011.08.009_bib0065","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.2042-7158.2010.01248.x","article-title":"p53-targeted cancer pharmacotherapy: move towards small molecule compounds","volume":"63","author":"Kim","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.tox.2011.08.009_bib0070","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","article-title":"p53, the cellular gatekeeper for growth and division","volume":"88","author":"Levine","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.tox.2011.08.009_bib0075","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1006\/excr.2002.5526","article-title":"The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax\/mitochondrial\/caspase-9 pathway","volume":"276","author":"Luu","year":"2002","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.tox.2011.08.009_bib0080","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1093\/carcin\/bgq101","article-title":"p53 is balancing development, differentiation and de-differentiation to assure cancer prevention","volume":"31","author":"Molchadsky","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.tox.2011.08.009_bib0125","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jpba.2011.07.013","article-title":"Determinatino and stability of CP-31398 in plasma from experimental animals by LC\u2013MS\/MS","volume":"56","author":"Muzzio","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.tox.2011.08.009_bib0090","doi-asserted-by":"crossref","first-page":"8175","DOI":"10.1158\/0008-5472.CAN-09-1377","article-title":"Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of Celecoxib in male F34 rats","volume":"69","author":"Rao","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.tox.2011.08.009_bib0095","doi-asserted-by":"crossref","first-page":"7670","DOI":"10.1158\/0008-5472.CAN-08-1610","article-title":"Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator in APCmin\/+ mice","volume":"68","author":"Rao","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.tox.2011.08.009_bib0100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.oraloncology.2010.10.011","article-title":"p53-Reactivating small molecules induce apoptosis and enhance chemotherapic cytotoxicity in head and neck squamous cell carcinoma","volume":"47","author":"Roh","year":"2011","journal-title":"Oral Oncol."},{"key":"10.1016\/j.tox.2011.08.009_bib0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4161\/cbt.1.1.41","article-title":"The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis in human cancer cells and can stabilize wild-type p53 protein","volume":"1","author":"Takimoto","year":"2002","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.tox.2011.08.009_bib0110","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1172\/JCI32481","article-title":"CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice","volume":"117","author":"Tang","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tox.2011.08.009_bib0115","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.4161\/cbt.203","article-title":"Restoring p53-dependent tumor suppression","volume":"2","author":"Wang","year":"2003","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.tox.2011.08.009_bib0120","doi-asserted-by":"crossref","first-page":"6566","DOI":"10.1158\/0008-5472.CAN-10-0942","article-title":"Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis","volume":"70","author":"Xu","year":"2010","journal-title":"Cancer Res."}],"container-title":["Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X11003003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X11003003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T23:16:59Z","timestamp":1759533419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300483X11003003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":24,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0300483X11003003"],"URL":"https:\/\/doi.org\/10.1016\/j.tox.2011.08.009","relation":{},"ISSN":["0300-483X"],"issn-type":[{"value":"0300-483X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subchronic oral toxicity and metabolite profiling of the p53 stabilizing agent, CP-31398, in rats and dogs","name":"articletitle","label":"Article Title"},{"value":"Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tox.2011.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ireland Ltd. Published by Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}